Welcome to LookChem.com Sign In|Join Free

CAS

  • or

53478-05-0

1,3-Benzenedicarboxylic acid, 5-(phenylmethoxy)-, monomethyl ester is a complex organic compound with the chemical formula C16H14O6. It is a derivative of benzene dicarboxylic acid, featuring a benzene ring with two carboxyl groups at the 1 and 3 positions. The 5-position of the benzene ring is substituted with a phenylmethoxy group, which is a benzyl ether. One of the carboxyl groups is esterified with a methyl group, making it a monomethyl ester. 1,3-Benzenedicarboxylic acid, 5-(phenylmethoxy)-, monomethyl ester is known for its potential applications in the synthesis of pharmaceuticals and other organic compounds, particularly in the area of drug development. It is characterized by its molecular structure, which includes a benzene ring with functional groups that can participate in various chemical reactions, making it a versatile intermediate in organic synthesis.

53478-05-0 Suppliers

Post Buying Request

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier
  • 53478-05-0 Structure

  • Basic information

    1. Product Name: 1,3-Benzenedicarboxylic acid, 5-(phenylmethoxy)-, monomethyl ester
    2. Synonyms:
    3. CAS NO:53478-05-0
    4. Molecular Formula: C16H14O5
    5. Molecular Weight: 286.284
    6. EINECS: N/A
    7. Product Categories: N/A
    8. Mol File: 53478-05-0.mol

  • Chemical Properties

    1. Melting Point: N/A
    2. Boiling Point: N/A
    3. Flash Point: N/A
    4. Appearance: N/A
    5. Density: N/A
    6. Refractive Index: N/A
    7. Storage Temp.: N/A
    8. Solubility: N/A
    9. CAS DataBase Reference: 1,3-Benzenedicarboxylic acid, 5-(phenylmethoxy)-, monomethyl ester(CAS DataBase Reference)
    10. NIST Chemistry Reference: 1,3-Benzenedicarboxylic acid, 5-(phenylmethoxy)-, monomethyl ester(53478-05-0)
    11. EPA Substance Registry System: 1,3-Benzenedicarboxylic acid, 5-(phenylmethoxy)-, monomethyl ester(53478-05-0)

  • Safety Data

    1. Hazard Codes: N/A
    2. Statements: N/A
    3. Safety Statements: N/A
    4. WGK Germany:
    5. RTECS:
    6. HazardClass: N/A
    7. PackingGroup: N/A
    8. Hazardous Substances Data: 53478-05-0(Hazardous Substances Data)

53478-05-0 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 53478-05-0 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 5,3,4,7 and 8 respectively; the second part has 2 digits, 0 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 53478-05:
(7*5)+(6*3)+(5*4)+(4*7)+(3*8)+(2*0)+(1*5)=130
130 % 10 = 0
So 53478-05-0 is a valid CAS Registry Number.

53478-05-0Relevant articles and documents

COMPOUNDS, IN PARTICULAR FOR USE IN THE TREATMENT OF A DISEASE OR CONDITION FOR WHICH A BROMODOMAIN INHIBITOR IS INDICATED

-

Page/Page column 50, (2016/01/25)

The invention relates to a compound for use in the treatment of a disease or condition for which a bromodomain inhibitor is indicated characterized by a general formula (1) and a compound according to formula (3).

(3-HYDROXY-4-AMINO-BUTAN-2-YL) -3- (2-THIAZOL-2-YL-PYRROLIDINE-1-CARBONYL) BENZAMIDE DERIVATIVES AND RELATED COMPOUNDS AS BETA-SECRETASE INHIBITORS FOR TREATING

-

Page/Page column 108, (2009/05/29)

The present invention provides novel beta-secretase inhibitors and methods for their use, including methods of treating of Alzheimer's disease. (Formula)

De novo Design and synthesis of N-benzylanilines as new candidates for VEGFR tyrosine kinase inhibitors

Uno, Masaharu,Ban, Hyun Seung,Nabeyama, Wataru,Nakamura, Hiroyuki

scheme or table, p. 979 - 981 (2009/02/05)

N-Benzylanilines were designed and synthesized as vascular endothelial growth factor (VEGF)-2 inhibitors using de novo drug design systems based on the X-ray structure of VEGFR-2 kinase domain. Among compounds synthesized, compound 3 showed the most potent inhibitory activity toward VEGFR-2 (KDR) tyrosine kinase and its IC50 value was 0.57 μM.

RENIN INHIBITORS

-

Page/Page column 22, (2008/12/05)

The present invention relates to disubstituted piperidinyl renin inhibitor compounds having the structure (Formula I) and their use in treating cardiovascular events and renal insufficiency.

BACE-1 inhibitors Part 1: Identification of novel hydroxy ethylamines (HEAs)

Clarke, Brian,Demont, Emmanuel,Dingwall, Colin,Dunsdon, Rachel,Faller, Andrew,Hawkins, Julie,Hussain, Ishrut,MacPherson, David,Maile, Graham,Matico, Rosalie,Milner, Peter,Mosley, Julie,Naylor, Alan,O'Brien, Alistair,Redshaw, Sally,Riddell, David,Rowland, Paul,Soleil, Virginie,Smith, Kathrine J.,Stanway, Steven,Stemp, Geoffrey,Sweitzer, Sharon,Theobald, Pam,Vesey, David,Walter, Daryl S.,Ward, John,Wayne, Gareth

, p. 1011 - 1016 (2008/12/20)

Inhibition of the aspartyl protease BACE-1 has the potential to deliver a disease-modifying therapy for Alzheimer's disease. Herein, is described the lead generation effort which resulted, with the support of X-ray crystallography, in the discovery of pot

QUINOXALINES AS B RAF INHIBITORS

-

Page/Page column 63-64, (2010/11/08)

The invention relates to chemical compounds of the formula (I) or pharmaceutically acceptable salts thereof, which possess B Raf inhibitory activity and are accordingly useful for their anti cancer activity and thus in methods of treatment of the human or animal body. The invention also relates to processes for the manufacture of said chemical compounds, to pharmaceutical compositions containing them and to their use in the manufacture of medicaments of use in the production of an anti-cancer effect in a warm blooded animal such as man.

QUINAZOLINONE DERIVATIVES AND THEIR USE AS B-RAF INHIBITORS

-

Page/Page column 66, (2008/06/13)

The invention relates to chemical compounds of the formula (I): or pharmaceutically acceptable salts thereof, which possess B Raf inhibitory activity and are accordingly useful for their anti cancer activity and thus in methods of treatment of the human or animal body. The invention also relates to processes for the manufacture of said chemical compounds, to pharmaceutical compositions containing them and to their use in the manufacture of medicaments of use in the production of an anti-cancer effect in a warm blooded animal such as man.

MACROCYCLIC TERTIARY AMINE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE

-

Page/Page column 71, (2010/11/08)

The present invention is directed to macrocyclic tertiary amine compounds represented by general formula (I), which are inhibitors of the beta-secretase enzyme and that are useful in the treatment of diseases in which the beta-secretase enzyme is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the treatment of such diseases in which the beta-secretase enzyme is involved.

HYDROXYETHYLAMINE DERIVATIVES FOR THE TREATMENT OF ALZHEIMER'S DISEASE

-

Page 29, (2010/02/07)

The present invention relates to novel hydroxyethylamine compounds of formula (I): (I) having Asp2 (-secretase, BACE1 or Memapsin) inhibitory activity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases characterised by elevated-amyloid levels or-amyloid deposits, particularly Alzheimer's disease.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 53478-05-0